IN2012DN01322A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01322A
IN2012DN01322A IN1322DEN2012A IN2012DN01322A IN 2012DN01322 A IN2012DN01322 A IN 2012DN01322A IN 1322DEN2012 A IN1322DEN2012 A IN 1322DEN2012A IN 2012DN01322 A IN2012DN01322 A IN 2012DN01322A
Authority
IN
India
Prior art keywords
antibody
cmet
prognosis
disorders associated
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of IN2012DN01322A publication Critical patent/IN2012DN01322A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN1322DEN2012 2009-08-21 2010-08-23 IN2012DN01322A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23586409P 2009-08-21 2009-08-21
EP09305777A EP2287197A1 (fr) 2009-08-21 2009-08-21 Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer
US34800510P 2010-05-25 2010-05-25
PCT/EP2010/062271 WO2011020925A1 (fr) 2009-08-21 2010-08-23 Anticorps anti-cmet et son utilisation pour dépister et diagnostiquer le cancer

Publications (1)

Publication Number Publication Date
IN2012DN01322A true IN2012DN01322A (fr) 2015-06-05

Family

ID=41571045

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1322DEN2012 IN2012DN01322A (fr) 2009-08-21 2010-08-23

Country Status (19)

Country Link
US (2) US8673302B2 (fr)
EP (2) EP2287197A1 (fr)
JP (1) JP5951486B2 (fr)
KR (1) KR20120051734A (fr)
CN (1) CN102639564B (fr)
AR (1) AR077901A1 (fr)
AU (1) AU2010284944B2 (fr)
BR (1) BR112012003759A2 (fr)
CA (1) CA2769427C (fr)
ES (1) ES2692522T3 (fr)
IL (1) IL218202A (fr)
IN (1) IN2012DN01322A (fr)
MX (1) MX2012002139A (fr)
NZ (2) NZ700437A (fr)
RU (1) RU2582265C2 (fr)
SG (1) SG178339A1 (fr)
TW (1) TW201111781A (fr)
WO (1) WO2011020925A1 (fr)
ZA (1) ZA201202076B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287197A1 (fr) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
SG10201506881PA (en) * 2011-11-21 2015-10-29 Taivex Therapeutics Corp Biomarkers for cancers responsive to modulators of hec1 activity
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
CA2869316C (fr) * 2012-05-09 2016-12-20 Eli Lilly And Company Anticorps anti-c-met
HK1208181A1 (en) * 2012-06-21 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
WO2014128235A1 (fr) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Méthodes de traitement du cancer et de prévention de résistance aux médicaments
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031626A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de cmet soluble
WO2015031614A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de la cmet soluble
WO2015032695A1 (fr) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Procédé de notation pour l'expression de la protéine mésothéline
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
EP3229836B1 (fr) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Anticoprs monoclonaux contre 'axl'
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
KR20170128256A (ko) * 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
EP3411067B1 (fr) 2016-02-05 2021-10-20 Helixmith Co., Ltd Anticorps anti-cmet et leurs utilisations
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
RU2735918C2 (ru) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Набор реагентов для выявления маркера эпителиальных карцином
CN112351998B (zh) * 2018-06-29 2022-07-22 苏州智核生物医药科技有限公司 Pd-l1结合多肽及其用途
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
US20220252603A1 (en) * 2019-06-06 2022-08-11 Apollomics Inc. (Hangzhou) Method for treating cancer patients using c-met inhibitor
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
JP7510518B2 (ja) 2020-09-01 2024-07-03 レメゲン シーオー．，エルティーディー． 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用
CA3191363A1 (fr) * 2020-09-08 2022-03-17 Ideaya Biosciences, Inc. Combinaison pharmaceutique et traitement antitumoral
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
CA3251953A1 (fr) * 2022-06-09 2023-12-14 Santa Ana Bio, Inc. Anticorps ciblant c-kit et/ou siglec et leurs utilisations
AU2023317484A1 (en) 2022-07-30 2025-03-13 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
EP4763865A1 (fr) * 2023-08-14 2026-06-24 Minghui Pharmaceutical (Hangzhou) Limited Nanocorps anti-c-met et son utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
WO2003057155A2 (fr) * 2001-12-27 2003-07-17 Van Andel Research Institute Imagerie par anticorps monoclonaux et traitement de tumeurs exprimant met et se liant au facteur de croissance des hepatocytes
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
WO2007056523A2 (fr) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Procedes de diagnostic et de surveillance de la progression d'un cancer
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
EP2014681A1 (fr) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (fr) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer

Also Published As

Publication number Publication date
CA2769427C (fr) 2020-03-10
US8673302B2 (en) 2014-03-18
AR077901A1 (es) 2011-09-28
IL218202A (en) 2017-07-31
SG178339A1 (en) 2012-03-29
MX2012002139A (es) 2012-03-07
TW201111781A (en) 2011-04-01
EP2467402A1 (fr) 2012-06-27
WO2011020925A1 (fr) 2011-02-24
KR20120051734A (ko) 2012-05-22
CN102639564A (zh) 2012-08-15
NZ700437A (en) 2016-04-29
CA2769427A1 (fr) 2011-02-24
US20140295452A1 (en) 2014-10-02
EP2467402B1 (fr) 2018-08-01
JP2013502213A (ja) 2013-01-24
JP5951486B2 (ja) 2016-07-13
RU2012109004A (ru) 2013-09-27
CN102639564B (zh) 2015-01-07
AU2010284944A1 (en) 2012-03-08
ES2692522T3 (es) 2018-12-04
EP2287197A1 (fr) 2011-02-23
IL218202A0 (en) 2012-04-30
AU2010284944B2 (en) 2016-01-28
BR112012003759A2 (pt) 2017-07-11
US20120149031A1 (en) 2012-06-14
ZA201202076B (en) 2012-11-28
NZ598194A (en) 2015-05-29
RU2582265C2 (ru) 2016-04-20

Similar Documents

Publication Publication Date Title
PH12012502466A1 (en) Novel antibody for the diagnosis and/or prognosis of cancer
MX2012002139A (es) Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
GB0718967D0 (en) Peptide imaging agents
WO2011015944A3 (fr) Utilisation d'adn libre en tant que prédicteur précoce de la gravité d'une pancréatite aiguë
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
EP2502628A3 (fr) Séquences de polynucléotides et de polypeptides impliquées dans le cancer
WO2011011426A8 (fr) Procédés d'évaluation d'un risque de maladie
MX2008009886A (es) Anticuerpos que enlazan par-2.
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
WO2010115745A3 (fr) Biomarqueurs, procédés et kits de diagnostic de la polyarthrite rhumatoïde
EP2585826A4 (fr) Méthodes et compositions pour diagnostiquer et pronostiquer une lésion rénale et une insuffisance rénale
WO2010041046A8 (fr) Protéines de granine en tant que marqueurs de maladie cardiaque
WO2010140834A3 (fr) Aptamère d'acide nucléique se liant spécifiquement à des tissus ou à des cellules cancéreuses du pancréas, et utilisation afférente
WO2007080597A3 (fr) Nouvelles séquences de nucléotides et d'acides aminés et leurs procédés d'utilisation pour le diagnostic
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
GB0815846D0 (en) diagnosis, prognosis and imaging of disease
WO2014117680A3 (fr) Utilisation des niveaux d'arn messager du gène trpc6 dans des cellules du sang périphérique pour le dépistage/diagnostic précoce de la démence sénile
WO2012006394A3 (fr) Hmga2 en tant que biomarqueur pour le diagnostic et le pronostic du cancer des ovaires
WO2013063412A3 (fr) Méthodes de diagnostic et de traitement d'états associés au stress du réticulum endoplasmique (re)
NZ605640A (en) Signal biomarkers
WO2007120311A3 (fr) Détection de peptides solubles du récepteur de l'adiponectine et utilisation dans le diagnostic et la thérapeutique
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
WO2012003493A3 (fr) Mutation génétique de la protéine kinase ck2, amplifications et polymorphismes dans les cancers humains, et procédés d'utilisation
WO2012088105A3 (fr) Procédés et compositions pour prédire l'état de maladie dans un cancer